Anji Pharma Secures China Rights to Apo E Mimetic Platform from LipimetiX Development

Lead peptide AEM-28 has demonstrated remarkable VLDL cholesterol and triglyceride reductions in Phase 1 and Phase 2 human clinical trials.

Anji Pharma launches a global strategy to accelerate medicines to China and other markets

​Anji Pharma, a new global pharmaceutical company tackling biological targets with exquisite validation from human genetics, launched earlier this year.

1 / 1

Please reload

©2018 BY ANJI PHARMA